ArticleFrontiers in endocrinology2026
Association between the stress hyperglycemia ratio and neovascular glaucoma in patients with proliferative diabetic retinopathy.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neovascular glaucoma (NVG) is a sight-threatening complication of proliferative diabetic retinopathy (PDR). The stress hyperglycemia ratio (SHR), which quantifies the discrepancy between acute admission glucose and chronic glycemic background, has been associated with adverse outcomes in diabetic populations, but its relationship with NVG remains unknown. Objective: To examine the association between the SHR and prevalent NVG among patients with PDR. Methods: In this retrospective cross-sectional study, patients with PDR presenting to Shaoxing People's Hospital between 2023 and 2025 were categorized according to NVG status (49 with NVG; 215 without). The SHR was calculated as admission blood glucose (mmol/L) ÷ (1.59 × HbA1c - 2.59). Multivariable logistic regression estimated adjusted odds ratios (aORs), with the per-0.1-unit SHR increment as the primary effect measure; Firth penalized regression and a model excluding HbA1c were fitted as sensitivity analyses. Non-normally distributed variables were compared using the Mann-Whitney U test, with a Bonferroni-adjusted threshold of 0.0063 for the eight baseline comparisons. Discrimination was internally validated by bootstrap resampling. Results: Patients with NVG were younger (median 57.0 vs. 62.0 years; p < 0.001) and had higher SHR values (median 0.96 vs. 0.82; p < 0.001). The SHR was independently associated with prevalent NVG (aOR per 0.1-unit increment 1.31, 95% CI 1.12-1.53; p < 0.001); the Firth-penalized estimate was nearly identical (aOR 1.29, 95% CI 1.11-1.50). The events-per-variable ratio was 6.1; subgroup estimates were statistically unstable and are reported as exploratory only. The optimism-corrected C-statistic was 0.724. Conclusions: In this cross-sectional analysis, an elevated SHR was associated with a higher prevalence of NVG among patients with PDR. Because established NVG may itself increase admission glucose through acute stress, reverse causation cannot be excluded. These hypothesis-generating findings require confirmation in prospective, externally validated cohorts before any clinical application can be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.